NCT06963320 - Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty | Biotech Hunter

Enrollment

320

Participants

Timeline

Start Date

January 20, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

July 30, 2025

Conditions

Circulatory Disease

Interventions

DRUG

H001 Capsule 200mg-qd

H001 Capsule, 50 mg/capsule, 200 mg orally once daily for 10-14 days.

DRUG

Enoxaparin Sodium Injection

Enoxaparin Sodium Injection,0.4 mL: 4000 AXaIU, 40 mg subcutaneously once daily for 10-14 days

DRUG

H001 Capsule 300mg-qd

H001 Capsule, 50 mg/capsule, 300 mg orally once daily for 10-14 days.

DRUG

H001 Capsule 200mg-bid

H001 Capsule, 50 mg/capsule, 200 mg orally twice daily for 10-14 days.

Trial Locations (1)

RECRUITING

Shanghai Sixth People's Hospital, Shanghai